Table 4.

ORs between TLR4 haplotypes and the risk of prostate cancer

HaplotypePrevalence among controls, % (95% CI)Global test P = 0.02P*
0 copies1 copy2 copies
Case/controlORCase/controlOR (95% CI)Case/controlOR (95% CI)
Hap1: GGATATGAGAGGTGC25.2 (22.9-27.5)340/3931.00309/2571.40 (1.12-1.75)51/471.25 (0.82-1.90)0.01
Hap2: AAATATGAGAGGTGC25.0 (23.1-27.7)403/3871.00250/2700.89 (0.71-1.11)47/391.15 (0.74-1.80)0.41
Hap3: AAATATGAGACGTGC13.1 (11.3-14.8)526/5281.00164/1551.07 (0.83-1.37)9/140.64 (0.28-1.50)0.50
Hap4: AGGCGCAGTAGGTGC7.3 (6.0-8.7)618/5971.0079/980.78 (0.56-1.07)3/21.46 (0.24-8.77)0.27
Hap5: AGGCGCAGTAGCCGA5.6 (4.5-6.9)651/6191.0049/790.59 (0.41-0.86)0/00.01
Hap6: AGGCGTAATAGCCAA5.2 (4.0-6.3)638/6301.0061/620.95 (0.65-1.39)1/50.22 (0.03-1.73)0.26
  • * P tested the null hypothesis: OR1 copy = OR2 copies = 1.